Wszystkie pola: "20351327" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer.
Autorzy:: Zhou Z; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhang B; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Deng Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Deng S; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Li J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wei W; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wang Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wang J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Feng Z; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Che M; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Yang X; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Meng J; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Li Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Hu Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Sun Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wen L; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Huang F; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Sheng Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wan C; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .; Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, China. .; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .
Yang K; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .; Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, 430022, China. .; Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Jan 29; Vol. 43 (1), pp. 34. Date of Electronic Publication: 2024 Jan 29.
Typ publikacji:: Journal Article
MeSH Terms:: Large Neutral Amino Acid-Transporter 1*/genetics
Lung Neoplasms*/genetics
Lung Neoplasms*/radiotherapy
F-Box-WD Repeat-Containing Protein 7*/genetics
RNA-Binding Proteins*/genetics
Animals ; Mice ; Cell Line, Tumor ; Glycogen Synthase Kinase 3 beta/genetics ; RNA ; Radiation Tolerance

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer.
Autorzy:: Oliveira TB; Medical Oncology Department, AC Camargo Cancer Center, São Paulo 01509-001, Brazil.
Fontes DMN; Nurse Navigator Department, AC Camargo Cancer Center, São Paulo 01509-001, Brazil.
Montella TC; Medical Oncology Department, Oncoclínicas, Rio de Janeiro 22250-905, Brazil.
Lewgoy J; Medical Oncology Department, Hospital Mãe de Deus, Porto Alegre 90880-481, Brazil.
Dutra C; Medical Oncology Department, Clínica Soma, Florianópolis 88020-210, Brazil.
Miola TM; Nutritional Oncology Department, AC Camargo Cancer Center, São Paulo 01509-001, Brazil.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Dec 29; Vol. 31 (1), pp. 183-202. Date of Electronic Publication: 2023 Dec 29.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/therapy
Lung Neoplasms*/therapy
Humans ; Quality of Life ; Health Personnel ; Immunotherapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
Autorzy:: Sathiyapalan A; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON L8V 5C2, Canada.; Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
Baloush Z; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON L8V 5C2, Canada.; Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
Ellis PM; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON L8V 5C2, Canada.; Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Oct 29; Vol. 30 (11), pp. 9514-9529. Date of Electronic Publication: 2023 Oct 29.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Combined Modality Therapy ; Nivolumab/therapeutic use ; Disease-Free Survival

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non-small cell lung cancer from proteomic profiling of circulating extracellular vesicles.
Autorzy:: Torasawa M; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Horinouchi H; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yagishita S; Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan.
Utsumi H; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Okuda K; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takekoshi D; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Ito S; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Wakui H; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Murata S; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kaku S; Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan.
Okuma K; Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Matsumoto Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Shinno Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Okuma Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Goto Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yamamoto N; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Araya J; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Fujita Y; Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.; Division of Next-Generation Drug Development Research, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Oct; Vol. 14 (29), pp. 2909-2923. Date of Electronic Publication: 2023 Aug 24.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/therapy
Lung Neoplasms*/therapy
Pneumonia*/chemically induced
Humans ; Consolidation Chemotherapy ; Retrospective Studies ; NF-kappa B ; Proteomics ; Chemoradiotherapy/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Efficacy and toxicity of stereotactic body radiotherapy for un-resectable stage III non-small cell lung cancer patients unfit for concurrent chemoradiation therapy: a retrospective study.
Autorzy:: Jia Z; Department of Radiation Oncology, Shanghai Changhai Hospital Affiliated to Navy Medical University, 168 Changhai Road, Shanghai, 200433, China.
Fang F; Department of Radiation Oncology, Shanghai Changhai Hospital Affiliated to Navy Medical University, 168 Changhai Road, Shanghai, 200433, China.
Cao Y; Department of Radiation Oncology, Shanghai Changhai Hospital Affiliated to Navy Medical University, 168 Changhai Road, Shanghai, 200433, China.
Zhu X; Department of Radiation Oncology, Shanghai Changhai Hospital Affiliated to Navy Medical University, 168 Changhai Road, Shanghai, 200433, China.
Yang X; Department of hepatic surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, 255 Changhai Road, Shanghai, 200433, China.
Guo X; Department of Radiation Oncology, Shanghai Changhai Hospital Affiliated to Navy Medical University, 168 Changhai Road, Shanghai, 200433, China.
Zhang H; Department of Radiation Oncology, Shanghai Changhai Hospital Affiliated to Navy Medical University, 168 Changhai Road, Shanghai, 200433, China. .; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2023 Aug 24; Vol. 18 (1), pp. 140. Date of Electronic Publication: 2023 Aug 24.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/radiotherapy
Radiosurgery*/adverse effects
Lung Neoplasms*/radiotherapy
Humans ; Retrospective Studies ; Chemoradiotherapy/adverse effects ; Disease Progression

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study.
Autorzy:: Guan S; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Ren K; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Zhang X; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Yan M; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Li X; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Zhao L; Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China. .; Tianjin's Clinical Research Center for Cancer, Tianjin, China. .; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. .; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2023 Jul 25; Vol. 18 (1), pp. 122. Date of Electronic Publication: 2023 Jul 25.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/therapy
Lung Neoplasms*/therapy
Humans ; Retrospective Studies ; Neoplasm Staging ; Chemoradiotherapy/methods ; Immunotherapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.
Autorzy:: Li W; Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wan L; Department of Pharmacy, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Jun 01; Vol. 18 (6), pp. e0286595. Date of Electronic Publication: 2023 Jun 01 (Print Publication: 2023).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Cost-Benefit Analysis ; Chemoradiotherapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
Autorzy:: Wu L; Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zhang Z; Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
Bai M; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yan Y; Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Yu J; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. .
Xu Y; Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. .; Pokaż więcej
Źródło:: Cell communication and signaling : CCS [Cell Commun Signal] 2023 May 23; Vol. 21 (1), pp. 119. Date of Electronic Publication: 2023 May 23.
Typ publikacji:: Video-Audio Media; Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Humans ; Immune Checkpoint Inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Autorzy:: Kim H; Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea.
Park S; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sun JM; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn JS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2023 Apr; Vol. 55 (2), pp. 498-505. Date of Electronic Publication: 2022 Oct 04.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Neoplasms*/therapy
Lung Neoplasms*/drug therapy
Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Squamous Cell*/pathology
Brain Neoplasms*/therapy
Brain Neoplasms*/drug therapy
Humans ; Retrospective Studies ; Incidence ; Neoplasm Staging ; Mutation ; ErbB Receptors/genetics ; Protein Kinase Inhibitors/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.
Autorzy:: Petrella F; Department of Thoracic Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
Rizzo S; Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Via Tesserete 46, 6900 Lugano, Switzerland.; Faculty of Biomedical Sciences, University of Italian Switzerland, Via Buffi 13, 6900 Lugano, Switzerland.
Attili I; Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Passaro A; Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Zilli T; Faculty of Biomedical Sciences, University of Italian Switzerland, Via Buffi 13, 6900 Lugano, Switzerland.; Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, 6500 Bellinzona, Switzerland.; Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.
Martucci F; Radiation Oncology, Oncological Institute of Southern Switzerland, EOC, 6500 Bellinzona, Switzerland.
Bonomo L; Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Via Tesserete 46, 6900 Lugano, Switzerland.
Del Grande F; Service of Radiology, Imaging Institute of Southern Switzerland (IIMSI), EOC, Via Tesserete 46, 6900 Lugano, Switzerland.; Faculty of Biomedical Sciences, University of Italian Switzerland, Via Buffi 13, 6900 Lugano, Switzerland.
Casiraghi M; Department of Thoracic Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.
De Marinis F; Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Spaggiari L; Department of Thoracic Surgery, European Institute of Oncology IRCCS, 20141 Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Mar 07; Vol. 30 (3), pp. 3160-3175. Date of Electronic Publication: 2023 Mar 07.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Neoplasm Staging ; Combined Modality Therapy ; Neoadjuvant Therapy

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy.
Autorzy:: Mori M; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Kanayama M; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Kuwata T; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Manabe T; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Nemoto Y; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Nishizawa N; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Oyama R; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Matsumiya H; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Nabe Y; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Taira A; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Takenaka M; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Yoneda K; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Kuroda K; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan.
Tanaka F; Second Department of Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, 807-8555, Japan. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Feb 25; Vol. 13 (1), pp. 3270. Date of Electronic Publication: 2023 Feb 25.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/metabolism
Lung Neoplasms*/metabolism
Humans ; Prognosis ; Programmed Cell Death 1 Receptor ; Chemoradiotherapy ; Receptors, Immunologic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study.
Autorzy:: Boys E; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Blacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Gao B; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Blacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Hui R; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
da Silva I; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Blacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Hau E; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Blacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Gee H; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Nagrial A; Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, New South Wales, Australia.; Blacktown Cancer and Haematology Centre, Blacktown Hospital, Blacktown, New South Wales, Australia.; Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Feb; Vol. 14 (6), pp. 563-572. Date of Electronic Publication: 2023 Jan 10.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Humans ; Antibodies, Monoclonal/therapeutic use ; Chemoradiotherapy/methods ; Neoplasm Staging

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?
Autorzy:: Diong NC; Division of Thoracic Surgery, Department of Surgery, Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia.
Liu CC; Division of Thoracic Surgery, Department of Surgery, Koo Foundation Sun Yat-Sen Cancer Center, 125, Lide Road, Beitou District, Taipei, 11259, Taiwan. .
Shih CS; Division of Thoracic Surgery, Department of Surgery, Koo Foundation Sun Yat-Sen Cancer Center, 125, Lide Road, Beitou District, Taipei, 11259, Taiwan.
Wu MC; Department of Medical Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
Huang CJ; Department of Pulmonary Medicine and Intensive Care Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
Hung CF; Department of Research, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.; Pokaż więcej
Źródło:: World journal of surgical oncology [World J Surg Oncol] 2022 Nov 26; Vol. 20 (1), pp. 370. Date of Electronic Publication: 2022 Nov 26.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/surgery
Lung Neoplasms*/drug therapy
Lung Neoplasms*/surgery
Humans ; Protein Kinase Inhibitors/therapeutic use ; Combined Modality Therapy ; Lung

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
Autorzy:: Huang Y; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Zhao JJ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Soon YY; Department of Radiation Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Wong A; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Aminkeng F; Department of Pharmacology, National University of Singapore, Singapore, Singapore.
Ang Y; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Asokumaran Y; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Low JL; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Lee M; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Choo JRE; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Chan G; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Kee A; Department of Medicine, Respiratory Medicine Division, National University Hospital, Singapore, Singapore.
Tay SH; Department of Medicine, Rheumatology Division, National University Hospital, Singapore, Singapore.
Goh BC; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.
Soo RA; Department of Haematology-Oncology, National University Cancer Institute Singapore, Singapore, Singapore.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2022 Nov; Vol. 13 (22), pp. 3152-3161. Date of Electronic Publication: 2022 Sep 30.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Carcinoma, Non-Small-Cell Lung*/therapy
Chemoradiotherapy*
Lung Neoplasms*/pathology
Lung Neoplasms*/therapy
Antineoplastic Agents, Immunological*/therapeutic use
Humans ; ErbB Receptors/therapeutic use ; Neoplasm Recurrence, Local/etiology ; Neoplasm Staging ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Autorzy:: Yang RX; Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.
Hei Y; Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.
Zhu WT; Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.
Wang QR; Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.
Zhang HM; Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.
Chen Y; Department of Oncology, Xijing Hospital of Air Force Military Medical University, Xi'an 710032, China.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Aug 29; Vol. 29 (9), pp. 6203-6210. Date of Electronic Publication: 2022 Aug 29.
Typ publikacji:: Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Adjuvants, Immunologic/therapeutic use ; Female ; Humans ; Immunotherapy ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC.
Autorzy:: Borghetti P; Radiation Oncology Department, ASST Spedali Civili and Brescia University, Brescia, Italy. .
Imbrescia J; Radiation Oncology Department, ASST Spedali Civili and Brescia University, Brescia, Italy.
Volpi G; Radiation Oncology Department, ASST Spedali Civili and Brescia University, Brescia, Italy.
Scotti V; Radiation Oncology Unit, Oncology Department AOU Careggi Firenze, Firenze, Italy.
Aquilano M; Radiation Oncology Unit, Oncology Department AOU Careggi Firenze, Firenze, Italy.
Bruni A; Radiotherapy Unit, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Franceschini D; IRCCS Humanitas Research Hospital - Radiotherapy and Radiosurgery Department, Milan, Italy.
Ursino S; Radiation Oncology Unit, University Hospital Santa Chiara Pisa, Pisa, Italy.
Ciammella P; Radiotherapy Unit, Department of Oncology and Advanced Technologies, AUSL-IRCCS, Reggio Emilia, Italy.
Piperno G; Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Taraborrelli M; Radiation Oncology Unit, 'SS Annunziata' Hospital, 'G. D'Annunzio' University, Chieti, Italy.
Magrini SM; Radiation Oncology Department, ASST Spedali Civili and Brescia University, Brescia, Italy.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2022 Jul 16; Vol. 17 (1), pp. 124. Date of Electronic Publication: 2022 Jul 16.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Aged ; Antibodies, Monoclonal ; Chemoradiotherapy ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors.
Autorzy:: Sobol B; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Azzam Nieto O; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Eberlein EL; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Scherr AL; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Ismail L; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Kessler A; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Nader L; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Schwab M; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.
Hoffmeister P; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Schmitt N; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Jäger D; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Welte S; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Seidensaal K; Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Christopoulos P; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.; Translational Lung Research Center, German Center for Lung Research (DZL) at Heidelberg University Hospital, 69120 Heidelberg, Germany.
Heilig C; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Kriegsmann K; Department of Hematology, Oncology and Rheumatology, University of Heidelberg, 69120 Heidelberg, Germany.
Fröhling S; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Kriegsmann M; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany.
Hess J; Molecular Mechanisms of Head and Neck Tumors, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.; Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Köhler BC; Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, University Hospital Heidelberg, 69120 Heidelberg, Germany.; German Cancer Consortium (DKTK), 69120 Heidelberg, Germany.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Jul 16; Vol. 23 (14). Date of Electronic Publication: 2022 Jul 16.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/radiotherapy
Head and Neck Neoplasms*/radiotherapy
Lung Neoplasms*/pathology
Lung Neoplasms*/radiotherapy
Sarcoma, Synovial*
Apoptosis ; Cell Line, Tumor ; Humans ; Myeloid Cell Leukemia Sequence 1 Protein/genetics ; Myeloid Cell Leukemia Sequence 1 Protein/metabolism ; Proto-Oncogene Proteins c-bcl-2 ; Squamous Cell Carcinoma of Head and Neck/radiotherapy ; bcl-X Protein/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT.
Autorzy:: Wurstbauer K; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria. .
Kazil M; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.
Meinschad M; Academic Teaching Hospital, Institute of Medical Physics, Feldkirch, Austria.
Pinter R; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.
De Vries C; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.
Clemens P; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.
Kreuter C; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.
Hernler T; Department for Pneumology, Academic Teaching Hospital, Hohenems, Austria.
Hitzl W; Team Biostatistics and Publication of Clincial Studies, FM&TT, Paracelsus Medical University, Salzburg, Austria.
Cerkl P; Department for Pneumology, Academic Teaching Hospital, Hohenems, Austria.
Künzler T; Academic Teaching Hospital, Institute of Medical Physics, Feldkirch, Austria.
De Vries A; Department for Radiation Oncology, Academic Teaching Hospital, Carinagasse 47, 6800, Feldkirch, Austria.; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2022 Jul 07; Vol. 17 (1), pp. 120. Date of Electronic Publication: 2022 Jul 07.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Humans ; Lung/pathology ; Prospective Studies ; Radiotherapy Dosage

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Predictive value of post-treatment C-reactive protein-to-albumin ratio in locally advanced non-small cell lung cancer patients receiving durvalumab after chemoradiotherapy.
Autorzy:: Araki T; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Tateishi K; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Komatsu M; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Sonehara K; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Wasamoto S; Department of Respiratory Medicine, Saku Central Hospital Advanced Care Center, Saku, Japan.
Koyama S; Department of Respiratory Medicine, Japanese Red Cross Society Nagano Hospital, Nagano, Japan.
Yoshiike F; Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
Hama M; Department of Respiratory Medicine, Japanese Red Cross Society Suwa Hospital, Suwa, Japan.
Nishie K; Department of Respiratory Medicine, Iida Municipal Hospital, Iida, Japan.
Kondo D; Department of Respiratory Medicine, Hokushin General Hospital, Nakano, Japan.
Agatsuma T; Department of Respiratory Medicine, Shinshu Ueda Medical Center, Ueda, Japan.
Kato A; Department of Respiratory Medicine, Ina Central Hospital, Ina, Japan.
Takata M; Department of Respiratory Medicine, Jiseikai Aizawa Hospital, Matsumoto, Japan.
Kanda S; Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.
Hanaoka M; First Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Koizumi T; Department of Hematology and Medical Oncology, Shinshu University School of Medicine, Matsumoto, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2022 Jul; Vol. 13 (14), pp. 2031-2040. Date of Electronic Publication: 2022 May 26.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Antibodies, Monoclonal ; C-Reactive Protein ; Chemoradiotherapy ; Humans ; Neoplasm Staging

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Autorzy:: Zheng Q; Department of Thoracic Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610044, People's Republic of China.
Min S; Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610044, People's Republic of China.
Zhou Y; Department of Thoracic Surgery, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610044, People's Republic of China. yunf_zhou_.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2022 Jun 20; Vol. 22 (1), pp. 674. Date of Electronic Publication: 2022 Jun 20.
Typ publikacji:: Journal Article; Meta-Analysis
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/etiology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/etiology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin ; Chemoradiotherapy/adverse effects ; Chemoradiotherapy/methods ; Cisplatin/adverse effects ; Docetaxel/therapeutic use ; Etoposide/therapeutic use ; Humans ; Irinotecan/therapeutic use ; Network Meta-Analysis ; Paclitaxel ; Pemetrexed/therapeutic use ; Vinorelbine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""20351327"" wg kryterium: Wszystkie pola

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język